1. Scrip
  2. >>Archive

Kymab names Groendahl CEO, Chiswell as chair

 
• By Lucie Ellis-Taitt

Biopharmaceutical firm Kymab, which develops fully human monoclonal antibodies, has named Dr Christian Groendahl and Dr David Chiswell chief executive officer and chair of the board, respectively. Dr Groendahl joins the Cambridge, UK-based firm from Zealand Pharma where he was chief scientific officer. Meanwhile Dr Chiswell has previously been chair of a number of biotechnology companies – including Nabriva Therapeutics, Sosei, and Daniolabs – and is currently non-executive chair of Albireo Pharma and a director of Nabriva Therapeutics. He joined the Kymab board in 2012. Both appointments are effective from 16 September 2013.

Biopharmaceutical firm Kymab, which develops fully human monoclonal antibodies, has named Dr Christian Groendahl and Dr David Chiswell chief executive officer and chair of the board, respectively. Dr Groendahl joins the Cambridge, UK-based firm from Zealand Pharma where he was chief scientific officer. Meanwhile Dr Chiswell has previously been chair of a number of biotechnology companies – including Nabriva Therapeutics, Sosei, and Daniolabs – and is currently non-executive chair of Albireo Pharma and a director of Nabriva Therapeutics. He joined the Kymab board in 2012. Both appointments are effective from 16 September 2013.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Post-BIO Podcast: Thoughts From The Frontlines

 
• By Sarah Karlin-Smith, Mandy Jackson, and Mary Jo Laffler

Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Kymera Inks CDK2 Deal With Gilead

 
• By Alaric DeArment

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.